Bibliografía
 

2.- Josephson M, Buxton A, Marchlinski F. The tachyarrhythmias. In: Harrison, et al eds. Principles of Internal Medicine. Ed. McGraw-Hill. New York 1992. 

3.- Patton J, Wood D, Gersh B. Sistema de conducción cardiaco. En Brandenburg,et al (eds). Cardiología. Fundamentos y práctica. Ed. CEA. Madrid 1989.

4.- Epstein A, Hallstrom A, Rogers W, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. JAMA 1993; 270: 2451-2455.

5.- Pfisterer M, Kiowski W, Brunner H, et al. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993; 87: 309-311.

6.- Camm A, Obel O. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996; 78: 3A-11A.

7.- Wolf P, Abbott R, Kannel W. Atrial fibrillation as independent risk factor for stroke.: the Framingham study. Stroke 1991; 22: 983-988. 

8.- Giardina E. Atrial fibrillation and stroke: elucidating a newly discoverd risk factor. Am J Cardiol 1997; 80: 11D-18D.

9.- Wolf P, Abbott R, Kannel W. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med 1987; 147: 1561-1564

10.- Anderson J. Acute treatment of atrial fibrillation and flutter. Am J Cardiol 1996; 78: 17A-21A.

11.- Carlsson T, Tebbe V, Rox J, et al. Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 1996; 78: 1380-1384.

12.- Kerber R. Transthoracic cardioversion of atrial fibrillation and fltter: Standard techniques and new advances. Am J Cardiol 1996; 78: 22A–26A.

13.- Yurchak P, Williams S, Achord J, et al. Clinical competence in elective direct current (DC) cardioversion. Circulation 1993; 88: 342-345.

14.- Arnold A, Mick M, Mazurek R, et al. Role of prophylactic anticoagulation for direct current cardioversion in patient with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855.

15.- Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108: 352S-359S.

16.- Manning W, Silverman D, Gordon S, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-755.

17.- Jones E, Calafiore P, McNeil J, et al. Atrial fibrillation with left atrial spontaneous contract detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996; 78: 425-429.

18.- Lee S, Chen S, Tai C, et al. Comparison of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997; 79: 905-908.

19.- Stroobandt R, Stiels B, Hoebrechts R, et al. Propafenone for cardioversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997; 79: 418-423.

20.- Coplen S, Antman E, Berlin J, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rythm: a meta-analysis of randomized clinical trials. Circulation 1990; 82: 1106-1116.

21.- Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Conpenhagen AFASAK study. Lancet 1989; 1: 175-179.

22.- European atrial fibrillation trial study group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 331: 5-10
.
23.- Leung D, Davidson P; Cranney G, et al. Thrmboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 1997; 79: 626-629. 

24.- García-Cosío F. Mecanismos del flúter y fibrilación auricular en el hombre. En Farré J, Moro C (eds): Arrítmias cardiacas: fundamentos y opciones terapéuticas. Ed. Edos. Barcelona 1992.

25.- Wilbur S, Marchlinski F. Adenosine as an antiarrhythmic agent Am J Cardiol 1997; 79(12A): 30-37.

26.- Barranco F, Sánchez M, Rodríguez J, et al. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intens Car Med. 1994; 20: 42-44.

27.- Ho D, Zecchin R, Richards D, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344: 18-23.

28.- The cardiac arryhthmia suppression trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.

29.- Yusuf S, Teo K. Approaches to prevention of sudden death: need for fundamented reevaluation. J Cardiovasc Electrophysiol 1991; 2: 233S-239S
.
30.- Mason J, for the electrophysiologic study versus electrocardiographic monitoring (ESVEM) investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329:452-458.

31.- The CASCADE investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. Am J Cardiol 1993; 72: 280-287.

32.- Block M, Hammel D, Böcker D, et al. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?. Am J Cardiol 1996; 78: 62A –68A.

33.- Julian D, Camm A, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarction amiodarone trial investigators. Lancet 1997; 349: 667-674. 

34.- Cairns J, Connolly S, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisation: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators. Lancet 1997; 349: 675-682.

35.- Waldo A, Camm A, deRuyter H, et al. SWORD investigators.Effect of d-Sotalol on mortality in patients with left ventricular dysfunction afer recent myocardial infarction. Lancet 1996; 348: 7-12.

36.- Mirowski M, Mower M, Staewen W, et al. Standby automatic defibrillator: an approach to prevention of sudden coronary death. Arch Intern Med 1970; 126: 158-161.

37.- Mirowski M, Reid P, Mower M, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human being. N Engl J Med 1980: 303: 322-324.

38.- Kenknight B, Jones B, Thomas A, Lang D. Technologial advances in implantable cardioverter-defibrillators before the year 2000 and veyhond. Am J Cardiol 1996; 78: 108A –115A.

39.- Gregoratos G, Cheitlin M, Conill A, et al. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 1988; 31: 1175-1209. 

40.- Kim S, Fisher J, Choue C, et al. Influence of left ventricular function on outcome of patients treated with implantable defibrillators. Circulation 1992; 85: 1304-1310.

41.- Siebels J, Kuck, K. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the cardiac arrest study Hamburg). Am Heart J 1994; 127: 1139-1144.

42.- Wever E, Hauer R, van Capelle F, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995; 91: 2195-2203.

43.- The AVID investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricualr arrhythmias. N Engl J Med 1997; 337: 1576-1583.

44.- Haverkamp W, Eckardt L, Borggrefe M, et al. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Am J Cardiol 1997; 80: 67G-73G.

45.- Iseri Ll. Déficit de magnesio y trastornos cardiacos. Am J Med (ed esp.) 1975; 1: 685.

46.- Antunes E, Brugada J, Steuven G, et al. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricualr tachycardia with anterograde conduction over an accessory pathway. Pace 1994; 17: 1515-1524.

47.- Vaughan Williams E. Classification of antiarrhythmic drugs.In: Sandoe E, et al eds. Symposium on cardiac arrhythmias. Ed AB Astra. Sdertalje 1970.

48.- Task force of the working group on arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of drugs based on the actions on antiarrhythmic mechanism. Circulation 1991; 84: 1831-1851.

49.- Landers M, Reiter M. General principles of antiarrhythmic therapy for ventricular tachyarrhythmias. Am J Cardiol 1997; 80: 31G-44G
.
50.- Patton J, Wood D, gersh B. Sistema de conducción cardiaco. En: Brandenburg R, et al eds. Cardiología: fundamentos y práctica. Ed. CEA. Madrid 1989.

51.- Rasmussen K. Chronic sinus node disease: natural course and indications for pacing. Eur Heart J 1981; 2: 455-459.

52.- Zipes D, DiMarco J, Gillette P, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablaction procedures. J Am Coll Cardiol 1995; 26: 555-573.

53.- Damato A, Lau S, Helfant R, et al. A study of heart block in man using His bundle recording. Circulation 1969; 39: 297-305.

54.- Barold S. Indications of permanent cardiac pacing in first-degree AV block: class I, II ó III ?. Pace 1996; 19: 747-751.

55.- Ryan T, Anderson J, Antman E, et al. Guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology / American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 1996; 28: 1328-1428.

56.- Zipes D. Cardiac pacemakers and antiarrhythmia devices. In: Braunwald E. (ed). Heart disease: a textbook of Cardiovascular Medicine. Ed Saunders. Philadelphia 1992.

57.- Rodríguez J, Coma R, Tello R, Curcio A. Indicaciones y modos de estimulación cardiaca en los noventa. En : Fernández F, et al.(eds). Puesta al dia. Arrítmias cardiacas. Revista Española de Cardiología. Madrid 1995.